JAVIER BOTAS

Associate Professor

Universidad Rey Juan Carlos

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Javier Botas is an Associate Professor at Universidad Rey Juan Carlos in Spain. His research primarily focuses on cardiovascular health, particularly in relation to cholesterol, coronary interventions, and the effects of pharmacological treatments on cardiac outcomes. He has contributed to significant studies on the implications of statin therapy and patient adherence in cardiac rehabilitation.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (6)

Jorge Ferreira

MD, Head of Inpatient Unit

PORTUGAL

View details

Antonio J Quesada

Head of the Clinical Trials Coordination Unit

Centro Nacional de Investigaciones Cardiovasculares (CNIC)

SPAIN

View details

Roberto Latini

Head if the Dept.

Istituto di Ricerche Farmacologiche Mario Negri

ITALY

View details

jan cornel

Professor

Radboud University Medical Center

NETHERLANDS

View details

J. Wouter Jukema

Leiden University Medical Center

NETHERLANDS

View details

Gonzalo Pizarro

Chief of Department

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

JAVIER BOTAS

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES.

Left ventricular outflow tract pseudoaneurysm causing coronary systolic compression.

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction

Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023).

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.

[Role of statins in clinical evolution of octogenarian patients admitted due to COVID-19].

Incidence and prognosis of late readmission after percutaneous coronary intervention.

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).

Adherence to physical exercise by women after completing a cardiac rehabilitation program,Adherencia al ejercicio físico en mujeres tras completar un programa de rehabilitación cardiaca

Collaborators (6)

Jorge Ferreira

Antonio J Quesada

Roberto Latini

jan cornel

J. Wouter Jukema

Gonzalo Pizarro

Make your next move.